Abstract

Background: Disease testis (CT) antigens, regularly communicated in human germline cells yet not in physical tissues, may become unusually reexpressed in various malignant growth types. The expression of CT antigens in breast cancer was the focus of this study.

Patients and methods: Immunohistochemistry was used to examine the expression of NY-ESO-1 and MAGE-A in a total of 100 selected invasive breast cancers, 50 of which were estrogen receptor (ER) positive/HER2 negative and 50 of which were triple negative (TN).

Results: MAGE-A and NY-ESO-1 expression was found to be significantly higher in TN breast cancers than in ERpositive tumors (P = 0.04). P = 0.07, MAGE-A expression was found in 13 (26%) TN cancers and 5 (10) ER-positive tumors. Nine (18%) TN tumor samples had NY-ESO-1 expression, while only two (4%) ER-positive tumors did.

Conclusions: A significant number of TN breast cancers express the MAGE-A and NY-ESO-1 CT antigens. Due to the restricted helpful choices for this gathering of patients, CT antigen-based antibodies could end up being valuable for patients with this aggregate of bosom malignant growth.